IL-6 plays a pathogenic role in inflammatory diseases.11 The balance of immune cells and cytokines inthe lung, disrupted by lung cancer, makes these elements key biomarkersfor immunotherapy efficacy.12 In a clinicalstudy examining various cytokines (IL-2, IL-4, IL-6, IL-10, IL-17A,TNF, and IFN-γ), only IL-6 showed a significant increase inthe level of NSCLC patients. Here, IL6 is linked to non-small cell lung carcinoma.